PROJECT HEMOREGEN-721 | IMMUNE SYNAPSE EV SIGNALING ARCHITECTURE | Blueprint for Antigen-Directed Extracellular Vesicle Communication at the Immune Synapse

SCF-VIRA-EVCM-0004

IMMUNE SYNAPSE EV SIGNALING ARCHITECTURE

Blueprint for Antigen-Directed Extracellular Vesicle Communication at the Immune Synapse

Document Code: SCF-VIRA-EVCM-0004

Program: PROJECT HEMOREGEN-721

Classification: SCF Viragenesis + DBI Immune Communication Module

Status: Foundational Blueprint v1.0

Regulatory Orientation: Mechanistic Immunology | Translational Biomarker Discovery | EV-Based Immunotherapeutic Engineering

1. Objective

To define the immune synapse as a high-precision EV signaling interface where immune cells exchange molecular instructions through directed extracellular vesicle transfer.

This blueprint maps:

Domain	Function
Synapse Formation	Physical immune-cell docking
EV Polarization	Vesicle trafficking toward contact zone
Cargo Loading	Antigen, RNA, cytokine, receptor packaging
Address Coding	Target-cell recognition logic
Signal Transfer	Vesicle release and uptake
Immune Outcome	Activation, tolerance, exhaustion, memory, cytotoxicity

2. Core SCF Hypothesis

The immune synapse functions as a directed EV transmission gate.

Unlike systemic EV broadcast signaling, immune synapse EV signaling is:

Feature	Immune Synapse EV Logic
Directionality	One immune cell to a specific partner cell
Precision	Receptor-guided delivery
Cargo Fidelity	Antigen- and state-specific
Timing	Rapid and contact-dependent
Outcome	Immune decision enforcement

SCF Equation:

Immune Synapse Signal Output = Antigen Recognition × EV Cargo Fidelity × Address Accuracy × Receptor Processing × Feedback Control

3. Immune Synapse Node Architecture

Sender Cell	Receiver Cell	Synapse Type	EV Signaling Function
Dendritic cell	CD4 T cell	Antigen-presenting synapse	T-cell priming
Dendritic cell	CD8 T cell	Cross-presentation synapse	Cytotoxic activation
B cell	T follicular helper cell	Humoral synapse	Antibody class switching
T cell	B cell	Helper synapse	Germinal center instruction
NK cell	Target cell	Cytotoxic synapse	Killing authorization
CTL	Infected/tumor cell	Cytotoxic synapse	Granzyme/perforin coordination
Treg	Effector T cell	Suppressive synapse	Immune tolerance enforcement
Macrophage	T cell	Inflammatory synapse	Polarization and recall response

4. Immune Synapse EV Cargo Classes

Cargo Class	Examples	SCF Function
Antigenic Cargo	MHC-peptide complexes, tumor antigens, viral peptides	Targeted immune instruction
Regulatory RNA	miR-155, miR-146a, miR-21, lncRNAs	Gene-expression modulation
Cytokine Cargo	IL-2, IL-10, IFN-γ, TNF-α, TGF-β	Immune-state programming
Checkpoint Cargo	PD-L1, CTLA-4-associated proteins, FasL	Activation/exhaustion/tolerance tuning
Cytotoxic Cargo	Granzyme B, perforin-associated proteins	Target-cell elimination
Metabolic Cargo	NAD+, ATP-related signals, redox proteins	Immune metabolic synchronization
Epigenetic Cargo	Histone fragments, methylation regulators	Long-term immune memory or tolerance

5. Address Code System

Address Layer	Molecular Examples	Function
Synapse Adhesion Code	LFA-1, ICAM-1, CD2, CD58	Stable immune-cell docking
Antigen Recognition Code	TCR–MHC, BCR–antigen	Specific immune targeting
Costimulation Code	CD28, CD80/CD86, CD40/CD40L	Activation permission
Checkpoint Code	PD-1/PD-L1, CTLA-4/CD80/CD86	Signal restraint
Chemokine Code	CCR7, CXCR5, CXCR3, CCR5	Tissue and immune-zone routing
Phagocytic Clearance Code	Phosphatidylserine, CD47	Uptake versus immune evasion

6. Signaling Modes

Mode	Description	Biological Outcome
Priming Mode	APC EVs deliver antigenic and costimulatory signals to naïve T cells	Adaptive immune activation
Amplification Mode	Activated T-cell EVs reinforce nearby immune cells	Clonal expansion
Suppression Mode	Treg EVs deliver inhibitory cargo	Tolerance and inflammation control
Cytotoxic Mode	NK/CTL EVs support killing of infected or malignant cells	Target-cell clearance
Exhaustion Mode	Checkpoint-rich EVs propagate immune fatigue	Chronic infection or tumor escape
Memory Mode	Durable RNA/protein cargo imprints recall programming	Long-term immunity

7. SCF Immune Synapse EV Fault Architecture

Fault Node	EV Signaling Failure	Disease Consequence
Antigen Misrouting	Wrong antigenic EV delivery	Autoimmunity
Checkpoint Overload	PD-L1/CTLA-4-dominant EVs	Cancer immune escape
Cytokine Broadcast Leak	Excess inflammatory EV release	Cytokine storm, sepsis
Cargo Degradation	Low-fidelity RNA/protein transfer	Weak immune response
Address Collapse	Poor adhesion/receptor matching	Failed priming
Tolerance Failure	Defective Treg EV signaling	Chronic inflammation
Exhaustion Propagation	Persistent inhibitory EV loops	Viral persistence, tumor progression

8. Disease Application Map

Disease Context	Synapse EV Defect	SCF Therapeutic Strategy
Cancer	Tumor PD-L1 EVs suppress T cells	EV checkpoint interception
Chronic Viral Infection	Exhaustion EV loops persist	Restore T-cell activation fidelity
Autoimmunity	Self-antigen EV misrouting	Tolerogenic EV reprogramming
Sepsis	Hyperinflammatory EV broadcast	Cytokine-cargo dampening
Transplant Rejection	Donor antigen EV activation	Immune-silencing EV modulation
Vaccine Failure	Poor APC EV antigen delivery	Engineered antigen EV adjuvanting

9. SCF Engineering Blueprint

Engineering Module	Design Objective
APC-EV Vaccine Platform	Load MHC-peptide, CD80/CD86, IL-12 signals for T-cell priming
Treg-EV Tolerance Platform	Load IL-10, TGF-β, miR-146a for autoimmune suppression
NK/CTL-EV Cytotoxic Platform	Load tumor-homing ligands with granzyme/perforin-associated cargo
Checkpoint-Decoy EV Platform	Capture PD-L1 or suppressive ligands before T-cell exhaustion
Synapse Repair EV Platform	Restore LFA-1/ICAM and costimulation fidelity
Immune Memory EV Platform	Deliver durable RNA/protein signals to reinforce recall immunity

10. Translational Biomarker Panel

Biomarker Class	Candidate Markers
EV Identity	CD9, CD63, CD81
APC EVs	MHC-I, MHC-II, CD80, CD86, CD40
T-cell EVs	CD3, CD4, CD8, TCR-associated proteins
Treg EVs	FOXP3-associated cargo, CD25, CTLA-4, IL-10
NK/CTL EVs	NKG2D, granzyme B, perforin-associated proteins
Exhaustion EVs	PD-L1, PD-1, TIM-3, LAG-3
Inflammatory EVs	TNF-α, IL-1β, IL-6
Resolution EVs	IL-10, TGF-β, miR-146a

11. SCF Immune Synapse EV Signaling Index

Domain	Score
Antigen Specificity	0–20
Address Accuracy	0–20
Cargo Fidelity	0–20
Synapse Stability	0–20
Functional Immune Outcome	0–20

Total: 0–100

Score	Interpretation
80–100	High-fidelity immune synapse signaling
60–79	Functional but stress-adapted signaling
40–59	Immune drift
20–39	Synapse dysfunction
<20	Immune communication collapse

12. Strategic Research Deliverables

Code	Deliverable
SCF-VIRA-EVCM-0004A	APC-to-T Cell EV Priming Atlas
SCF-VIRA-EVCM-0004B	Treg EV Tolerance Architecture
SCF-VIRA-EVCM-0004C	NK/CTL Cytotoxic EV Blueprint
SCF-VIRA-EVCM-0004D	Tumor Immune-Escape EV Atlas
SCF-VIRA-EVCM-0004E	Viral Exhaustion EV Loop Map
SCF-VIRA-EVCM-0004F	Immune Synapse EV Biomarker Panel
SCF-VIRA-EVCM-0004G	Engineered Immune-Synapse EV Therapeutics Platform

13. SCF Five-Principle Alignment

SCF Principle	Immune Synapse EV Application
Targeted Drug Action	Antigen- and receptor-specific EV delivery
Pharmacokinetic Optimization	Synapse-localized transfer reduces systemic exposure
Metabolic Efficiency	EV cargo coordinates immune-cell energy state
Resistance Prevention	Multi-signal cargo reduces immune escape
Safety Profile	Tolerogenic and checkpoint-balanced EV design limits toxicity

Master Registry Index

SCF-VIRA-EVCM-0004 — Immune Synapse EV Signaling Architecture

SCF-VIRA-EVCM-0004A — APC-to-T Cell EV Priming Atlas

SCF-VIRA-EVCM-0004B — Treg EV Tolerance Architecture

SCF-VIRA-EVCM-0004C — NK/CTL Cytotoxic EV Blueprint

SCF-VIRA-EVCM-0004D — Tumor Immune-Escape EV Atlas

SCF-VIRA-EVCM-0004E — Viral Exhaustion EV Loop Map

SCF-VIRA-EVCM-0004F — Immune Synapse EV Biomarker Panel

SCF-VIRA-EVCM-0004G — Engineered Immune-Synapse EV Therapeutics Platform

SCF-VIRA-EVCM-0003 — Organ-to-Organ EV Communication Network

SCF-VIRA-EVCM-0002 — Blood EV Address Code Atlas

SCF-VIRA-EVCM-0001 — Blood EV Cargo Mapping Framework